A Phase Ⅱ Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non–Small-Cell Lung Cancer: TORG2241 (UBE-Q)Shinji Nakamichi, Hiroaki Okamoto, Katsuhiko Naoki et al.|Clinical Lung Cancer|2023Cited by 6
A randomized phase II study comparing nivolumab (NIVO) with carboplatin-pemetrexed (CbPEM) for patients (pts) with EGFR mutation-positive non-small cell lung cancer (NSCLC) who acquire resistance to tyrosine kinase inhibitors (TKIs) not due to a secondary T790M mutation (WJOG8515L).Hidetoshi Hayashi, Kazuhiko Nakagawa, Shunichi Sugawara et al.|Journal of Clinical Oncology|2021Cited by 5
P2.23-02 Prospective Observational Study of Cachexia and Its Effect on Systemic Therapy in Patients with Previously-Untreated Advanced NSCLC (NEJ050A)Naoki Furuya, K. Takahashi, Kiyonori Miura et al.|Journal of Thoracic Oncology|2023Cited by 2